EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics

Nok Yin Tam, Xiaoqi Wang, Grace Chung Yan Chan, Wai Po Kong, Wai Yin Chau, Xiuqiong Fu, Kwok-Yin Wong, Hong Lok Lung, Zhi-Ling Yu, Wei Shen Aik iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202503281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Nok Yin Tam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China. Hauptthemen laut MEDLINE: RNA, Small Interfering, RNAi Therapeutics, Ribonucleoproteins, Ribonucleoproteins, Small Nuclear. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNAi therapeutics can potentially address undruggable diseases. However, their full potential is stymied by delivery challenges. An siRNA delivery platform by remodeling the human U4 small nuclear ribonucleoprotein complex (snRNP) is developed. This remodeled protein‐siRNA complex (SmiRNP) serves as a biocompatible, modular, and customizable platform for attaching desired functional modules to overcome delivery hurdles. Here, it is demonstrated that the SmiRNP complex, by using siRNA against KRAS as a proof of principle, can deliver the siRNA into cells and protect it from nuclease degradation, allowing the siRNA to knockdown KRAS mRNA and protein levels, reduce cancer cell viability, and suppress tumor growth in vivo. This general strategy allows many more modular combinations and would enable the delivery of a wide spectrum of RNAi therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingRNAi TherapeuticsRibonucleoproteinsRibonucleoproteins, Small NuclearHumansAnimalsCell Line, TumorRNA InterferenceMiceProto-Oncogene Proteins p21(ras)

Stichwörter der Autor:innen

KRASRNAi therapeuticsprotein‐based delivery agentribonucleoprotein complexsiRNA delivery

Substanzen

RNA, Small InterferingRibonucleoproteinsProto-Oncogene Proteins p21(ras)Ribonucleoproteins, Small NuclearKRAS protein, human

Autor:innen und Institutionen

  • Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China.
  • School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, China.
  • State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.

ORCID-Profile: Wei Shen Aik

Zitieren

APA

Tam, N. Y., Wang, X., Chan, G. C. Y., Kong, W. P., Chau, W. Y., Fu, X., Wong, K. Y., Lung, H. L., Yu, Z. L., & Aik, W. S. (2025). Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503281

Vancouver

Tam NY, Wang X, Chan GCY, Kong WP, Chau WY, Fu X, et al. Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202503281

BibTeX
@article{Tam2025,
  author = {Tam, Nok Yin and Wang, Xiaoqi and Chan, Grace Chung Yan and Kong, Wai Po and Chau, Wai Yin and Fu, Xiuqiong and Wong, Kwok-Yin and Lung, Hong Lok and Yu, Zhi-Ling and Aik, Wei Shen},
  title = {Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202503281}
}
Kostenlos starten →